ArticleMedicine in drug discovery2021
Network bioinformatics analysis provides insight into drug repurposing for COVID-19.
Article in Medicine in drug discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 82 citations in OpenAlex.
- Viral Mechanisms and Drug Influences on Janus Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) Pathway in Human Coronaviruses Infection: A Systematic Review.Health science reports · 2026Review
- Applications of Artificial Intelligence in Drug Repurposing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Decoding the mechanism of Qingjie formula in the prevention of COVID-19 based on network pharmacology and molecular docking.Heliyon · 2024Article
- National-scale 1-km maps of hospital travel time and hospital accessibility in China.Scientific data · 2024Article
- Clinical development and informatics analysis of natural and semi-synthetic flavonoid drugs: A critical review.Journal of advanced research · 2024Review
- Systems biology approaches to identify driver genes and drug combinations for treating COVID-19.Scientific reports · 2024Article
- Advancement of Computational Design Drug Delivery System in COVID-19: Current Updates and Future Crosstalk- A Critical update.Infectious disorders drug targets · 2023Article
- Building a knowledge graph to enable precision medicine.Scientific data · 2023Article
- Identification of miRNA-mRNA Regulatory Networks Associated with Diabetic Retinopathy using Bioinformatics Analysis.Endocrine, metabolic & immune disorders drug targets · 2023Article
- A review of SARS-CoV-2 drug repurposing: databases and machine learning models.Frontiers in pharmacology · 2023Review
- Effect of an Inhibitor on the ACE2-Receptor-Binding Domain of SARS-CoV-2.Journal of chemical information and modeling · 2022Article
- Deep variational graph autoencoders for novel host-directed therapy options against COVID-19.Artificial intelligence in medicine · 2022Article
- Hybrid Approach to Identifying Druglikeness Leading Compounds against COVID-19 3CL Protease.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity.Molecular biomedicine · 2022Review
- Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates.Molecules (Basel, Switzerland) · 2022Review
- A global picture: therapeutic perspectives for COVID-19.Immunotherapy · 2022Review
- COVID-19 Drug Repurposing: A Network-Based Framework for Exploring Biomedical Literature and Clinical Trials for Possible Treatments.Pharmaceutics · 2022Article
- Drug repurposing for SARS-CoV-2 main protease: Molecular docking and molecular dynamics investigations.Biochemistry and biophysics reports · 2022Article
- Computational anti-COVID-19 drug design: progress and challenges.Briefings in bioinformatics · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 disease caused by the SARS-CoV-2 virus is a health crisis worldwide. While developing novel drugs and vaccines is long, repurposing existing drugs against COVID-19 can yield treatments with known preclinical, pharmacokinetic, pharmacodynamic, and toxicity profiles, which can rapidly enter clinical trials. In this study, we present a novel network-based drug repurposing platform to identify candidates for the treatment of COVID-19. At the time of the initial outbreak, knowledge about SARS-CoV-2 was lacking, but based on its similarity with other viruses, we sought to identify repurposing candidates to be tested rapidly at the clinical or preclinical levels. We first analyzed the genome sequence of SARS-CoV-2 and confirmed SARS as the closest virus by genome similarity, followed by MERS and other human coronaviruses. Using text mining and database searches, we obtained 34 COVID-19-related genes to seed the construction of a molecular network where our module detection and drug prioritization algorithms identified 24 disease-related human pathways, five modules, and 78 drugs to repurpose. Based on clinical knowledge, we re-prioritized 30 potentially repurposable drugs against COVID-19 (including pseudoephedrine, andrographolide, chloroquine, abacavir, and thalidomide). Our work shows how in silico repurposing analyses can yield testable candidates to accelerate the response to novel disease outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.